ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,917.17
0.00%
Dow Jones
43,559.59
0.35%
US Dollar vs MXN
20.33704
0.27%
Brent Oil
73.625
1.08%
Bitcoin
97,000.44
2.82%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. RAPT Therapeutics Inc (RAPT) Cotización

RAPT Therapeutics Inc

RAPT Therapeutics Inc (RAPT)

NASDAQ
1.00
-0.07
( -6.54% )
Actualizado: 09:05:38
Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Estadísticas y detalles clave

Último Precio
1.00
Postura de Compra
1.00
Postura de Venta
1.01
Volume Operado de la Acción
100,025
1.00 Rango del Día 1.07
1.00 Rango de 52 semanas 27.35
Capitalización de Mercado [m]
34.958M
Precio Anterior
1.07
Precio de Apertura
1.05
Hora
500
@
1
Última hora de negociación
09:05:38
Volumen financiero
US$ 103,031
Precio Promedio Ponderado
1.0301
Volumen promedio (3 m)
526,524
Acciones en circulación
34,958,253
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.32
Beneficio por acción (BPA)
-3.34
turnover
-
Beneficio neto
-116.8M

Acerca de RAPT Therapeutics Inc

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX... RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.rapt.com
Sede
Dover, Delaware, USA
Fundado
-
RAPT Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RAPT. The last closing price for RAPT Therapeutics was US$1.07. Over the last year, RAPT Therapeutics shares have traded in a share price range of US$ 1.00 to US$ 27.35.

RAPT Therapeutics currently has 34,958,253 shares in issue. The market capitalisation of RAPT Therapeutics is US$37.41 million. RAPT Therapeutics has a price to earnings ratio (PE ratio) of -0.32.

RAPT Últimas noticias

Más noticias

Form 8-K - Current report

15 Noviembre 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Noviembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

12 Noviembre 2024
Edgar (US Regulatory)

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing...

12 Noviembre 2024
GlobeNewswire Inc.

Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering...

11 Noviembre 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

08 Agosto 2024
Edgar (US Regulatory)

Form 8-K - Current report

08 Agosto 2024
Edgar (US Regulatory)

RAPT Therapeutics Reports Second Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing...

08 Agosto 2024
GlobeNewswire Inc.

Form 8-K - Current report

19 Julio 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

23 Mayo 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.59-37.1069182391.591.595110136851.15093995CS
4-0.74-42.52873563221.743.32110797901.78153054CS
12-1.29-56.33187772932.293.3215265241.82199918CS
26-3.01-75.06234413974.014.8314715992.57779385CS
52-12.66-92.679355783313.6627.3517222408.19710607CS
156-34.39-97.174343034835.3940.74147589414.52124856CS
260-20.5-95.348837209321.551.2095140137419.15353213CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
SKKSKK Holdings Limited
US$ 10.86
(138.16%)
2.68M
WORXSCWorx Corporation
US$ 2.15
(119.39%)
80.83M
CRNCCerence Inc
US$ 4.50
(59.57%)
7.99M
SPAISafe Pro Group Inc
US$ 4.3999
(37.50%)
34M
CDTConduit Pharmaceuticals Inc
US$ 0.1243
(34.67%)
405.44M
PYXSPyxis Oncology Inc
US$ 2.0101
(-47.38%)
6.59M
KURAKura Oncology Inc
US$ 10.02
(-37.02%)
5.21M
BLRXBioLineRx Ltd
US$ 0.3805
(-30.21%)
4.32M
AGFYAgrify Corporation
US$ 27.2093
(-29.80%)
260.84k
SHOTWSafety Shot Inc
US$ 0.11
(-26.67%)
1,000
CDTConduit Pharmaceuticals Inc
US$ 0.1243
(34.67%)
405.44M
AKTSAkoustis Technologies Inc
US$ 0.0995
(14.24%)
160.04M
NVDANVIDIA Corporation
US$ 144.33
(-1.07%)
126.36M
WORXSCWorx Corporation
US$ 2.15
(119.39%)
80.83M
ELABElevai Labs Inc
US$ 0.02015
(-5.84%)
60.3M

RAPT Discussion

Ver más
Monksdream Monksdream 3 meses hace
RAPT under $3
👍️0
Monksdream Monksdream 3 meses hace
RAPT new 52 week low
👍️0
Monksdream Monksdream 3 meses hace
RAPT new 52 low
👍️0
Monksdream Monksdream 4 meses hace
RAPT under $4
👍️0
Monksdream Monksdream 6 meses hace
RAPT new 52 week
👍️0
Monksdream Monksdream 7 meses hace
RAPT under $10
👍️0
tickersym tickersym 9 meses hace
Bargin prices!! Lets go!!
👍️0
Stockexpertpro Stockexpertpro 9 meses hace
RAPT Only 1 Patient had a problem out of 350 people enrolled in the trial

https://finance.yahoo.com/news/1-fda-puts-hold-two-125809258.html Fire sale down here lots of upgrades out last weeK
👍️0
StockLogistics StockLogistics 2 años hace
Surprised that no gap fill occurred prior to results expected near September 12, showing major strength buoyed by estimates of 50.00:

“8:04a ET 5/23/2022 - Benzinga
RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it has initiated its 16-week randomized, double-blind, placebo-controlled Phase 2b clinical trial to further evaluate the efficacy and safety of RPT193 as monotherapy in patients with moderate-to-severe atopic dermatitis (AD).”
👍️0
StockLogistics StockLogistics 2 años hace
12.16 gap fill over the next 14.5 weeks
👍️0
StockLogistics StockLogistics 2 años hace
12.16 gap fill over the next 14.5 weeks
👍️0
StockLogistics StockLogistics 2 años hace
15 weeks to go

8:04a ET 5/23/2022 - Benzinga
RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

Countdown to potential billions in revenue.
👍️0
StockLogistics StockLogistics 2 años hace
A ton of insider buying last week
👍️0
StockLogistics StockLogistics 2 años hace
Positive sentiment about billions that could be made from Rapt’s drug and pipe financing, perfect storm brewing
👍️0
Glider549 Glider549 3 años hace
It happens,,and more often than not doesn't.
That's why I'd trim, but leave some on the table.
👍️0
weasel4339 weasel4339 3 años hace
It's way up after hours bud
👍️0
Glider549 Glider549 3 años hace
Can't believe some of you did not take profits near the close.
Greed will kill ya.
👍️0
pennyfinder pennyfinder 3 años hace
Will do
👍️0
weasel4339 weasel4339 3 años hace
I'll keep n eye out. Let me knoe if u hear something about the price
👍️0
pennyfinder pennyfinder 3 años hace
Supposed to be. There’s no price set on the offering. They just said they’re raising $125M, they could be raising at $50… who knows… but the history has always been lower than the closing price. We will have to wait and see.
👍️0
weasel4339 weasel4339 3 años hace
This considered dilution?
👍️0
pennyfinder pennyfinder 3 años hace
LOL

https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-announces-proposed-public-offering-common
👍️0
make it happen make it happen 3 años hace
Most def. Idk how these companies even give a PT like that. Happens way to often and retails get blindsided. I wouldn't even do that if had all the power too.
👍️0
pennyfinder pennyfinder 3 años hace
Offering AH or tomorrow pre
👍️0
make it happen make it happen 3 años hace
Negative 1,000% plus operating margins. Only Phase 1 still, A long way to go...

Large negative lose percentages across the board on margins.

Only $0.22 revenue per share

Cash flow will burn all money before end of year.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -1,064.70%

Management Effectiveness
Return on Assets (ttm) -27.62%
Return on Equity (ttm) -50.34%

Income Statement
Revenue (ttm) 5.33M
Revenue Per Share (ttm) 0.22
Quarterly Revenue Growth (yoy) 30.70%
Gross Profit (ttm) 5.04M
EBITDA -55.53M
Net Income Avi to Common (ttm) -56.27M
Diluted EPS (ttm) -2.29

Balance Sheet
Total Cash (mrq) 98.41M
Total Cash Per Share (mrq) 3.93
Total Debt (mrq) N/A
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 9.21
Book Value Per Share (mrq) 3.69

Cash Flow Statement
Operating Cash Flow (ttm) -45.66M
Levered Free Cash Flow (ttm) -23.3M
👍️0
StockLogistics StockLogistics 3 años hace
This stock reported legitimate results of its study and is a short squeeze candidate imo if Reddit wanted to wake up to it
👍️0
Roadtojourney Roadtojourney 5 años hace
Not even 6 months old and already offering??
👍️0
crudeoil24 crudeoil24 5 años hace
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It is developing selective small molecules designed to modulate the critical immune responses underlying these diseases. It has discovered and advanced two drug candidates FLX475 and RPT193, which is engaged in targeting C-C motif chemokine receptor 4 (CCR4). Its drug discovery and development engine has identified CCR4 as a drug target that potentially has broad applicability in oncology and inflammatory diseases. Its lead oncology drug candidate FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory Treg cells into tumors. Its RPT193 drug candidate, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells), into allergically-inflamed tissues.
👍️0
crudeoil24 crudeoil24 5 años hace
42.00 > hod.

RAPT
👍️0
crudeoil24 crudeoil24 5 años hace
29.01 x 30.00

RAPT
👍️0
crudeoil24 crudeoil24 5 años hace
Multiple Nasdaq circuit breakers halts today

RAPT
👍️0
crudeoil24 crudeoil24 5 años hace
7.7M shares trading float >

RAPT
👍️0

Su Consulta Reciente

NASDAQ
RAPT
RAPT Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados